Status:
NOT_YET_RECRUITING
Effect of Dapagliflozin on Interleukin 10 in Sepsis
Lead Sponsor:
Minia University
Conditions:
Sepsis
Eligibility:
All Genders
18-70 years
Brief Summary
The goal of this observational study is to learn about the long-term effects of dapagliflozin as anti-inflammatory agents to improve organ dysfunction and decrease mortality on patients of both gender...
Detailed Description
64 Patients fulfilling the criteria for sepsis admitted to ICU will be allocated into 2 groups (32 patients in each group): * Dapagliflozin group: Patients will receive dapagliflozin at a dosage of 1...
Eligibility Criteria
Inclusion
- 64 adult patients of both sex, over the age of 18 years who were admitted to the ICU with sepsis and those who developed sepsis in the ICU.
Exclusion
- \- 1. Patient's refusal, pregnant and lactating patients. 2. Known allergy or intolerance to dapagliflozin. 3. Unable to receive enteral medication\& patients with chronic liver disease. 4. Shock 5. Patients with malabsorption disorders \& or receipt of total parenteral nutrition and on treatment with statins.
- 6\. Patients with a history of familial hyperlipidemia. 7. End-stage renal disease (ESRD) on regular dialysis. 8. Type 1 diabetes.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT07206160
Start Date
October 1 2025
End Date
November 1 2026
Last Update
October 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.